In a randomized open study, the combination of either prostaglandin El (PGE,) or pentoxifylline with controlled vascular training was compared with vascular training alone in patients with peripheral arterial occlusive disease in stage IIb. Forty-four patients were randomly assigned to treatment either of intensive vascular training alone (n=15) or in combination with either IV pentoxifylline (200 mg over 2 hours BID, n= 15) or PGE, (40 gg over 2 hours BID, n= 14). The basic therapy was a well-defined routine for vascular training, which was identical for all groups. The duration of therapy was 4 weeks. In all three test groups, there was a significant increase in the walking distance. There was a 119% increase in symptom-free walking distance in the exercise-only group. In comparison with exercise alone, the additional administration of pentoxifylline produced no greater effect; the increase was 105%. In contrast, administration of PGE, combined with exercise achieved a remarkable improvement of 604%. Between-group comparison revealed the significant superiority of treatment with PGE1 (P<.05). During the 1-year follow-up, there was a reduction in the walking performance in all groups, albeit of variable extent. In the exercise-only and the pentoxifylline groups, the maintained increase in walking distance was only 30% compared with baseline values before the beginning of therapy. In the PGE1 group, on the other hand, the maintained improvement was 149%. Nine of 14 patients were still in stage IIa of peripheral arterial occlusive disease 1 year after PGE1 therapy. (Circulation. 1994;90(818-822.) Key 
. The basic therapy was a well-defined routine for vascular training, which was identical for all groups. The duration of therapy was 4 weeks. In all three test groups, there was a significant increase in the walking distance.
There was a 119% increase in symptom-free walking distance in the exercise-only group. In comparison with exercise alone, the additional administration of pentoxifylline produced no greater effect; the increase was 105%. In contrast, administration of PGE, combined with exercise achieved a remarkable improvement of 604%. Between-group comparison revealed the significant superiority of treatment with PGE1 (P<.05). During the 1-year follow-up, there was a reduction in the walking performance in all groups, albeit of variable extent. In the exercise-only and the pentoxifylline groups, the maintained increase in walking distance was only 30% compared with baseline values before the beginning of therapy. In the PGE1 group, on the other hand, the maintained improvement was 149%. However, in studies available to date, PGE, was administered to patients who were resting supine. In contrast, we believed it was essential to let patients perform muscular exercise during and after the infusion, ie, while leg perfusion was improved.
The aim of this study was to compare the combined effect of a vasoactive substance, such as PGE, or pentoxifylline, and intensive vascular exercise with the effect of vascular exercise alone.
Methods
A total of 44 patients (33 men and 11 women) with stage lIb PAOD (age range, 42 to 81 years; mean, 60±9 years) were included in a randomized open trial. Mean body weight was 74±14 kg, and mean height was 168±9 cm. Mean blood pressure was 156/88±21/11 mm Hg, and heart rate averaged 75±9 beats per minute.
Included in the study were patients with PAOD of the lower extremities who were stable and in stage IIb of the disease, according to Fontaine's classification.
Further requirements were that the arterial occlusive disease had existed in this stage for more than 6 months and that it had been confirmed by intra-arterial digital subtraction angiography or conventional angiography that the stenosis or occlusion was of the upper leg or lower leg type. Maximum walking distance on the treadmill up a 5% slope at a walking pace of 3 km/h had to be at least 50 m and no more than 200 m. In addition, each patient's informed consent was required. Exclusion criteria were defined as pregnancy, decompensated heart failure, decompensated renal failure, hemodynamically relevant aortic or iliac arterial occlusion, presence of necrosis or pain at rest, respiratory insufficiency, joint problems affecting walking distance, myocardial infarction within the past 6 months, indispensable therapy with vasoactive drugs or drugs affecting peripheral perfusion, tendency to hypotonic collapse or orthostatic dysregulation (postural hypotension), severely impaired cardiac conduction, and known epilepsy. It was essential for inclusion in the trial that measurements of the pain-free walking distance, taken three times during the washout phase (14 days), differed by no more than 20%. A further requirement was the ability to withstand Psychological methods were used to motivate the patients to continue the training, and group therapy was offered to smokers to help them give up smoking. At the beginning of the study, 38 patients were heavy smokers and 6 were ex-smokers. Additional frequent risk factors were disturbed lipometabolism (n=25) and hypertension (n=30).
Symptom-free and maximum walking distances were determined at weekly intervals with patients on the treadmill ergometer (5% slope; walking speed, 3 km/h) as the target parameter for assessing treatment efficacy. Before and after therapy, laboratory investigations were carried out (blood cell count, SGOT, SGPIT, alkaline phosphatase, cholesterol, triglycerides, creatinine, fibrinogen, Quick, aPTT), and special rheological parameters were tested (plasma viscosity, erythrocyte aggregation). In addition, blood pressure and heart rate were monitored during the infusion, and ECG was checked weekly.
Statistical Analysis
Within-group analysis of the effects was carried out using the Wilcoxon signed rank test for matched pairs. Betweengroup comparison used single-factor ANOVA followed by the Scheffe test. Previous power calculations of the different groups were been difficult for the following reasons. First, the intensity of vascular training in the literature varies greatly, and systematic training has not previously been carried out or investigated. Second, the efficacy of PGE1 application during training was unknown. We therefore adopted the working hypothesis that administration of an expensive medicine (PGE1) only makes sense if after 4 weeks of maximum vascular training alone the increase in walking distance is less than 100% but it is at least 300% in combination with PGE1. To show this, small groups in a pilot study are adequate.
Therefore, based on our hypothesis, the power calculation showed that 15 patients in the training-only group and the PGE1 group are sufficient.
Results
In all three groups, there was a significant increase in pain-free walking distance, albeit at different levels of significance.
With physical exercise alone, symptom-free walking distance increased from an average of 72±34 to 158±99 m (P<.01), representing an increase of 119% compared with the baseline value ( Table 2 ). The additional administration of pentoxifylline was no more effective than vascular training alone. With these patients, there was an average increase from 75 ±41 m at the beginning to 154±+150 m at the end of treatment (+ 105%, P<.05).
In contrast, a marked increase in walking distance could be observed in the patients treated with PGE1 and vascular training. In these cases, pain-free walking distance increased from 81±23 to 570±727 m (+604%, P<.001). Compared with the results obtained in the two other test groups, the increase is fivefold or sixfold greater (Fig 1) .
Between-group comparison showed a significant difference in favor of PGE1 over the two other test groups (P<.05).
The clear superiority of PGE, is also evident when the other target parameter, the maximum walking distance, is considered (Fig 2) . With combined exercise and PGE1 therapy, the walking distance increased from an average of 158±95 to 744±697 m, corresponding to an increase of 371% compared with the baseline value (P<.001) ( Table 3) . Patients treated with exercise in combination with pentoxifylline showed an increase from 160±133 to 351±432 m (+119%, P<.01) during therapy. With vascular training alone, the maximum walking distance increased from 131±74 to 261±173 m (+99%, P<.001).
Between-group comparison with regard to maximum walking distance revealed significant superiority of PGE1 in combination with vascular training over training alone (P<.05).
If all patients with a pain-free walking distance of 1000 m at the end of therapy are excluded to eliminate excessive variability, the following results are obtained: in the PGE1 group (n=12), the pain-free walking distance increased from 80±21 to 290±123 m (+263%, P<.01) ( Forty-four patients were followed up for 1 year after vascular training. Although a reduction in the symptomfree walking distance was observed in all three groups, the extent of deterioration differed greatly (Fig 3) . In both the exercise-only group (96±52 m) and the pentoxifylline group (99±46 m), the walking distance remained barely 30% above pretreatment values. In contrast, patients in the PGE, group still showed a 149% increase in walking distance (202±91 m) after 1-year follow-up.
Of little success were our efforts at converting smokers: after 1 year, only 2 still did not smoke; the other 36 continued to smoke.
Discussion
The therapeutic aim in treating a patient with intermittent claudication is to increase the symptom-free walking distance by strict adherence to a walking exercise routine. Aside from this physical method of treatment, the group of drugs affecting peripheral perfusion is a possible therapeutic alternative in the conservative treatment of PAOD. 13 This study was designed to investigate whether drug therapy with PGE, or pentoxifylline can be considered a rational addition to walking exercise.
The therapeutic efficacy of both PGE1 and pentoxifylline in intermittent claudication has been shown in several double-blind studies.47'9"10'14 In those studies, however, the drugs were administered to patients rest- Ill- that the improvement in walking distance and muscular performance must be greater with PGE1 and exercise than with PGE, administration under resting conditions or with exercise alone.9
Our investigation was able to show that intensive vascular training (daily exercise duration of 4 hours) over 4 weeks can produce an improvement in walking distance of more than 100% and that combined pentoxifylline and exercise therapy is no more effective than exercise alone, whereas the combination of PGE1 and vascular training produces an impressive increase in walking distance. Our results are even more significant if one assumes that changes in treadmill performance may be multiplied twofold or threefold in assessing the significance for the patient's everyday life.13 This can, of course, be of great benefit to the patient, motivating him to regularly carry out his daily walking exercise to maintain or possibly improve the gain achieved in exercise tolerance.
Aside from specific effects of vasoactive drugs, we are now convinced that in vascular patients there is an important relation between restricted gait (atypical stress on joints and muscle groups, relieving posture) and the degree of intermittent claudication.1,2,17 Physiotherapy with its effect in terms of improved mobility of joints and tendons leads to a freer gait and improves the pattern of muscle strain. Effective exercise with expert guidance and observation by specialized vascular therapists can considerably improve performance in this respect.5s". '8'9 As also shown in other studies,3.9 this analysis of long-term observations showed that with PGE, a considerable therapeutic benefit is maintained even after 1-year follow-up. An explanation for this lasting effect of PGE1 (and also prostacyclins) in the posttherapy phase cannot be given.
A recently published multicenter study4 also demonstrated the clinical efficacy of PGE1 compared with pentoxifylline in the treatment of intermittent claudication. In the PGEl-treated patients (n=97), the symptom-free walking distance increased by 119% (median) compared with 85% (median) in the pentoxifylline group (n=98). All patients performed only mild daily walking exercise between inclusion in the trial and the end of hospitalization.
